Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 5, 2010

Primary Completion Date

March 5, 2013

Study Completion Date

April 19, 2013

Conditions
Age-Related MaculopathyAge-Related MaculopathiesEye DiseasesRetinal DegenerationMacular Degeneration
Interventions
BIOLOGICAL

RN6G

Intravenous, multiple dose, dose ranging from 5 mg/kg up to a maximum of 15 mg/kg

BIOLOGICAL

Placebo

Intravenous, multiple dose with experimental dose

Trial Locations (24)

14642

University of Rochester Medical Center, Rochester

University of Rochester, Rochester

29169

Hawthorne Pharmacy, West Columbia

Jay Markowitz and Associates, West Columbia

Palmetto Retina Center, LLC, West Columbia

South Carolina Neurological, West Columbia

30901

Ranjit K. Sethi, MD, PC, Augusta

30907

Clinical Specialists, LLC, Augusta

30909

Southeast Retina Center, PC, Augusta

33609

Retina Associates of Florida, PA, Tampa

33611

Hoye's Pharmacy, Tampa

78613

Specialty Compounding, Cedar Park

78705

Brian B. Berger, MD, PA, Austin

Retina Research Center, PLLC, Austin

78731

Sleep Medicine Consultants, Austin

79605

National Central Pharmacy, Abilene

79606

Abilene Surgery Center, Abilene

Heart and Vascular Institute, Abilene

Retina Research Institute of Texas, Abilene

95008

Retinal Diagnostic Center, Campbell

95032

American Institute of Research (Administrative Only), Los Gatos

95116

Neurology Center Rai Kumar, San Jose

95124

Harmeet Sachdev, MD, FAAN, San Jose

95128

Santa Clara Drug, San Jose

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY